Literature DB >> 5349624

Studies of interactions among drugs in man at the renal level: probenecid and sulfinpyrazone.

J M Perel, P G Dayton, M M Snell, T F Yü, A B Gutman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5349624     DOI: 10.1002/cpt1969106834

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

Review 1.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 3.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

4.  Drug interactions with urate excretion in man.

Authors:  D K Sommers; H S Schoeman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.

Authors:  H A Strong; R Angus; J Oates; J Sembi; P Howarth; A G Renwick; C F George
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

6.  Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.